Compare Flowserve Corporation Common Stock (FLS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flowserve Corporation Common Stock vs Repligen Corporation Common Stock — how do they compare? Flowserve Corporation Common Stock trades at $69.78 (market cap $8.92B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Flowserve Corporation Common Stock pays a 1.25% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flowserve Corporation Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| FLS | RGEN | |
|---|---|---|
Market Cap | $8.92B | $11.31B |
Volume | 1,398,986 | 1,216,919 |
Sector | Industrials | Health |
52-Week High | $92.04 | $194.57 |
52-Week Low | $50.41 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.51B | $11.20B |
Dividend Yield | 1.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLS trades at $71.47, up 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Revenue for 2025 was $4.73 billion, with a net income margin of 8.01%. Recent news includes a new CFO appointment and a quarterly dividend declaration.
The outlook is mixed: strong fundamentals and a consensus price target of $90.75 suggest upside, but technical weakness and a high P/E of 24.9 pose risks. Key opportunities include strategic acquisitions and nuclear market exposure, while headwinds include weak organic sales and rising debt levels noted by analysts.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flowserve Corporation Common Stock
Flowserve Corporation is a Texas-based manufacturer of engineered flow-control equipment, producing industrial pumps, mechanical seals, valves, and automation products through its Flowserve Pumps Division and Flow Control Division, serving the oil and gas, chemical, power, and water industries in more than 50 countries.
Read more on FLS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
